Related Experiment Video
Updated: Nov 13, 2025
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.1K
Pilots flying with insulin-treated diabetes.
David L Russell-Jones1,2, Ewan J Hutchison2, Graham A Roberts3,4,5
1University of Surrey, Guildford, UK.
Diabetes, Obesity & Metabolism
|March 12, 2021
Summary
Insulin-treated pilots with diabetes can now fly, challenging previous bans. Advances in diabetes management and monitoring ensure safety in aviation, updating clinical guidelines for treating pilots with diabetes.
Area of Science:
- Endocrinology
- Aerospace Medicine
- Public Health
Background:
- Historically, individuals with diabetes requiring insulin faced occupational restrictions in safety-critical roles like aviation.
- Fear of hypoglycaemia (low blood sugar) and subsequent incapacitation fueled these bans.
- Stereotypical views on diabetes management have been challenged by recent therapeutic and technological advancements.
Purpose of the Study:
- To consolidate current knowledge on diabetes management for insulin-treated pilots.
- To provide an updated resource for clinicians regarding aviation safety and diabetes.
- To address the evolving landscape of allowing insulin-treated individuals in safety-critical occupations.
Main Methods:
- Literature review synthesizing information on glucose regulation, diabetes pathophysiology, and insulin therapy.
- Analysis of safety data and policy changes in the aviation sector.
- Discussion of advancements in insulin delivery, glucose monitoring (including noninvasive techniques), and their impact on pilot safety.
Main Results:
- The aviation industry has pioneered the allowance of insulin-treated pilots, demonstrating successful safety integration.
- Several countries have revised their policies, moving away from traditional opposition due to accumulating safety evidence.
- Current evidence supports the safe operation of aircraft by carefully selected and managed insulin-treated pilots.
Conclusions:
- Recent innovations in diabetes care have significantly improved the safety profile for insulin-treated individuals in aviation.
- Clinicians need updated information to guide the assessment and management of pilots with diabetes on insulin.
- The review supports a paradigm shift towards evidence-based inclusion rather than exclusion in safety-critical roles for individuals with well-managed diabetes.
More Related Videos
05:52Insulin Injection and Hemolymph Extraction to Measure Insulin Sensitivity in Adult Drosophila melanogaster
Published on: June 30, 2011
20.1K
08:13Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
Published on: January 7, 2018
70.2K
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
391
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
391
01:27Insulin Formulations: Types and Delivery
385
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
385
01:22Diabetes Mellitus: Overview and Type I Subtype
4.2K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.2K
01:22Diabetes Mellitus: Type 2 and Gestational
3.7K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.7K
01:06Oral Hypoglycemic Agents: Glinides
386
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
386
01:15Hypoglycemia and Glucagon
520
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
520